Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq
PR Newswire•06/08/2026•06:46 ET
0
Whiz Insights
Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq PR Newswire
SHANGHAI, Aug. 6, 2026 /PRNewswire/ -- Attovia Therapeutics, a portfolio company of Qiming Venture Partners and clinical-stage biopharmaceutical leader, successfully listed on the Nasdaq on August 5, 2026 Beijing time. Attovia Therapeutics (Nasdaq: ATTO) issued shares at a price of $17.00 per share and opened at $21.00 per share, with an approximate market capitalization of $904 million.
Get started
Create a free account to read the full story.